glp-1 inhibitor What is and Its Receptor Agonists? GLP-1 Agonists - FAQ —

Its limitations must be taken into account when interpreting its results

These agents are recommended as first-line therapy by the American Diabetes Association and the European Society of Cardiology for patients with diabetes and underlying cardiovascular disease [4, 5]

Humphrey CD, Lawrence AC

The number of acute pancreatitis adverse events steadily increased from 16 in 2005 to 459 in 2023 (Q1-Q3), peaking in 2011, reflecting the growing clinical utilization of GLP-1 RAs (Figure 1)

A large volume of GLP-1 drugs was distributed by the retail pharmacies along with effective guidance on their handling and side effects by the pharmacist

Since none of the GLP-1RA are approved in pregnancy, a cohort study approved the potency of liraglutide, in early pregnancy, despite its adverse outcomes such as preterm birth, preeclampsia and gestational diabetes mellitus (GDM) (90)